Cagrilintide
Cagrilintide is a next-generation long-acting amylin analogue that marks a shift in metabolic medicine by moving beyond the well-known GLP-1 pathway. While drugs like semaglutide focus on the gut-brain axis to delay gastric emptying, cagrilintide mimics amylin—a hormone co-secreted with insulin that signals “satiety” directly to the brainstem.
Cagrilintide as a Monotherapy
When used alone, cagrilintide acts as a potent appetite suppressant. Unlike GLP-1 agonists, which can sometimes cause a “food aversion” feeling, amylin analogues tend to promote a more natural sensation of fullness. In clinical trials like REDEFINE 1, monotherapy doses (2.4mg) have shown body weight reductions of approximately 11.5% to 12% over 68 weeks. It is particularly effective at reducing "hedonic eating"—the urge to eat for pleasure rather than hunger—by modulating dopamine signaling in the brain's reward centers.
The SUPER Stack: Cagrilintide + Retatrutide
In the 2026 landscape of research peptides, the combination of Cagrilintide and Retatrutide is often referred to as a “Super Stack” due to its multi-pathway coverage. While Retatrutide is a triple-agonist targeting GLP-1, GIP, and Glucagon, adding Cagrilintide introduces a fourth metabolic lever.